This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"

Ascendis starts an observational study for achondroplasia

ACHieve is the observational study for achondroplasia sponsored by Ascendis Pharma and is now recruiting.

Orphan Drug Designation Granted for TransCon CNP

Ascendis Pharma A/S announced on the 28th February 2019, on the rare disease day that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation (ODD) to TransCon CNP.

The Norwegian Adult Achondroplasia Study

The Sunnaas Rehabilitation Hospital is conducting an observational study on the prevalence of medical complications in adults with achondroplasia and their impact on daily activities entitled "The Norwegian Adult Achondroplasia Study".

Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia

Observational Study Investigating Clinical & Anthropometric Characteristics of Children With Achondroplasia, conducted by Therachon, is an observational study to investigate natural history of achondroplasia. It is currently recruiting for a number of countries.

Lifetime Impact of Achondroplasia Study in Europe - LIAISE

LIAISE is the Lifetime Impact of Achondroplasia Study in Europe. It will gather information on the clinical and medical interventions of people with achondroplasia, individuals' and caregivers' quality of life and the impact of this condition on education, employment and social life.

Breaking news - Preliminary Phase 1 data for TransCon CNP

On the 28th Nov 2018, Ascendis Pharma A/S announced positive preliminary results from a phase 1 trial of TransCon CNP.
To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.